Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, with a focus on healthcare and sustainability. Founded in 1972 and based in Paris, London, and Milan, it manages over €4 billion in assets and has backed more than 500 companies.
AUM
€4.0B
Funds
13
vintages 2008–2025
Portfolio
107
Exits
38
Key facts
Recent exits
Myricx Bio
Biotech2026 · 4yr hold
PinCell
Biotech2025 · 6yr hold
Sphere Bio (formerly Sphere Fluidics)
MedTech2025 · 4yr hold
Verona Pharma
Biotech2025 · 6yr hold
Coverage notes
13 funds tracked, 145 portfolio companies (107 active · 38 realized). Verified weekly from public filings and deal announcements.
Sector breakdown
145 companiesBiotech
108 · 74%
MedTech
26 · 18%
HealthTech
8 · 6%
AI/ML
1 · 1%
Business Services
1 · 1%
Software
1 · 1%
Funds & portfolio
Every fund Sofinnova Partners has raised, with its portfolio companies. Hand-checked from public filings.
13 funds
Sofinnova Capital XILife Sciences VC2025 · 1yr€650M2 active
Unrealized
2 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech |  France | 2025 | |
| Biotech | France | 2025 |
ActitheraActive
BiotechFrance· Entry 2025
France· Entry 2025Bionyra PharmaActive
BiotechFrance· Entry 2025
France· Entry 2025Sofinnova Biovelocita IILife Sciences VC2025 · 1yr€100M1 active
Sofinnova Digital Medicine IVC2022 · 4yr€100M9 active · 1 realized
Unrealized
9 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| HealthTech |  UK | 2022 | |
| Biotech | France | 2024 | |
| HealthTech | France | 2024 | |
| HealthTech |  Germany | 2021 | |
| HealthTech |  US | 2025 | |
| AI/ML | Poland | 2026 | |
| HealthTech | France | 2023 | |
| HealthTech | Canada | 2023 | |
| HealthTech | UK | 2025 |
BioCorteXActive
HealthTechUK· Entry 2022
UK· Entry 2022BioptimusActive
BiotechFrance· Entry 2024
France· Entry 2024Cure51Active
HealthTechFrance· Entry 2024
France· Entry 2024deepcActive
HealthTechGermany· Entry 2021
Germany· Entry 2021Excelsior SciencesActive
HealthTechUS· Entry 2025
US· Entry 2025IngenixActive
AI/MLPoland· Entry 2026
KiroActive
HealthTechFrance· Entry 2023
France· Entry 2023L'école AIActive
HealthTechCanada· Entry 2023
Latent LabsActive
HealthTechUK· Entry 2025
UK· Entry 2025Realized
1 exit| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| HealthTech | US | 2022 | 2024 | Trade Sale | – |
Sofinnova Biovelocita ILife Sciences VC2022 · 4yr€50M2 active
Unrealized
2 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech |  Italy | 2023 | |
| Biotech | Italy | 2023 |
BioClecActive
BiotechItaly· Entry 2023
Italy· Entry 2023Forth TherapeuticsActive
BiotechItaly· Entry 2023
Italy· Entry 2023Sofinnova Capital XLife Sciences VC2021 · 5yr€472M26 active · 2 realized
Unrealized
26 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech | US | 2022 | |
| Biotech | Germany | 2023 | |
| Biotech | UK | 2022 | |
| Biotech | Italy | 2022 | |
| Biotech |  Denmark | 2023 | |
| MedTech | US | 2022 | |
| Biotech |  Switzerland | 2021 | |
| Biotech | Switzerland | 2021 | |
| Biotech | France | 2022 | |
| Biotech | US | 2021 | |
| MedTech | France | 2023 | |
| Biotech | US | 2021 | |
| Biotech | UK | 2021 | |
| Biotech | France | 2021 | |
| Biotech | US | 2021 | |
| Biotech | Denmark | 2021 | |
| Biotech | Italy | 2022 | |
| MedTech |  Ireland | 2021 | |
| Biotech | UK | 2021 | |
| Biotech |  Spain | 2023 | |
| Biotech | UK | 2021 | |
| Biotech | UK | 2022 | |
| Biotech | UK | 2021 | |
| Biotech | UK | 2023 | |
| Biotech | US | 2022 | |
| Biotech | US | 2022 |
Catamaran BioActive
BiotechUS· Entry 2022
US· Entry 2022DISCO PharmaceuticalsActive
BiotechGermany· Entry 2023
Germany· Entry 2023Elevara MedicinesActive
BiotechUK· Entry 2022
UK· Entry 2022Enthera PharmaceuticalsActive
BiotechItaly· Entry 2022
Italy· Entry 2022Freya BiosciencesActive
BiotechDenmark· Entry 2023
Denmark· Entry 2023GalvanizeActive
MedTechUS· Entry 2022
US· Entry 2022GlycoEraActive
BiotechSwitzerland· Entry 2021
Switzerland· Entry 2021Haya TherapeuticsActive
BiotechSwitzerland· Entry 2021
Switzerland· Entry 2021Home BiosciencesActive
BiotechFrance· Entry 2022
France· Entry 2022InspirnaActive
BiotechUS· Entry 2021
US· Entry 2021May HealthActive
MedTechFrance· Entry 2023
France· Entry 2023Mediar TherapeuticsActive
BiotechUS· Entry 2021
US· Entry 2021MironidActive
BiotechUK· Entry 2021
UK· Entry 2021Mnemo TherapeuticsActive
BiotechFrance· Entry 2021
France· Entry 2021Mozart TherapeuticsActive
BiotechUS· Entry 2021
US· Entry 2021Muna TherapeuticsActive
BiotechDenmark· Entry 2021
Denmark· Entry 2021NanoPhoriaActive
BiotechItaly· Entry 2022
Italy· Entry 2022Neurent MedicalActive
MedTechIreland· Entry 2021
Ireland· Entry 2021NodTheraActive
BiotechUK· Entry 2021
UK· Entry 2021Nuage TherapeuticsActive
BiotechSpain· Entry 2023
Spain· Entry 2023PurespringActive
BiotechUK· Entry 2021
UK· Entry 2021Redona TherapeuticsActive
BiotechUK· Entry 2022
UK· Entry 2022Sitryx TherapeuticsActive
BiotechUK· Entry 2021
UK· Entry 2021T-TherapeuticsActive
BiotechUK· Entry 2023
UK· Entry 2023Tenpoint TherapeuticsActive
BiotechUS· Entry 2022
US· Entry 2022WerewoolActive
BiotechUS· Entry 2022
US· Entry 2022Realized
2 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech | France | 2022 | 2023 | Trade Sale | – | ||
| Biotech | UK | 2022 | 2026 | Trade Sale | – |
Sofinnova Industrial BiotechVC2018 · 8yr€200M20 active · 2 realized
Unrealized
20 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech | France | 2019 | |
| Biotech | US | 2022 | |
| Biotech | Denmark | 2018 | |
| Biotech |  Belgium | 2019 | |
| Biotech | UK | 2015 | |
| Biotech | US | 2019 | |
| Biotech | France | 2017 | |
| Biotech | France | 2019 | |
| Biotech |  Sweden | 2019 | |
| Business Services | France | 2019 | |
| Biotech | France | 2016 | |
| Biotech | France | 2019 | |
| Biotech |  Finland | 2017 | |
| Biotech | France | 2019 | |
| Biotech | France | 2019 | |
| Biotech | Spain | 2021 | |
| Biotech | US | 2022 | |
| Biotech | US | 2020 | |
| Biotech |  Netherlands | 2021 | |
| Biotech | France | 2021 |
AfyrenActive
BiotechFrance· Entry 2019
France· Entry 2019ArzedaActive
BiotechUS· Entry 2022
US· Entry 2022BiosyntiaActive
BiotechDenmark· Entry 2018
Denmark· Entry 2018BiotalysActive
BiotechBelgium· Entry 2019
Belgium· Entry 2019CelluCompActive
BiotechUK· Entry 2015
UK· Entry 2015DMC BiotechnologiesActive
BiotechUS· Entry 2019
US· Entry 2019DNA ScriptActive
BiotechFrance· Entry 2017
France· Entry 2017Elicit PlantActive
BiotechFrance· Entry 2019
France· Entry 2019EnginZymeActive
BiotechSweden· Entry 2019
Sweden· Entry 2019EnobraqActive
Business ServicesFrance· Entry 2019
France· Entry 2019GFBiochemicalsActive
BiotechFrance· Entry 2016
France· Entry 2016MeiogenixActive
BiotechFrance· Entry 2019
France· Entry 2019MetGenActive
BiotechFinland· Entry 2017
Finland· Entry 2017Micropep TechnologiesActive
BiotechFrance· Entry 2019
France· Entry 2019MicrophytActive
BiotechFrance· Entry 2019
France· Entry 2019NovameatActive
BiotechSpain· Entry 2021
Spain· Entry 2021Prometheus MaterialsActive
BiotechUS· Entry 2022
US· Entry 2022ProteraActive
BiotechUS· Entry 2020
US· Entry 2020QoriumActive
BiotechNetherlands· Entry 2021
Netherlands· Entry 2021BiotechFrance· Entry 2021
France· Entry 2021Realized
2 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech | Netherlands | 2016 | 2017 | IPO | – | – | |
| Software | France | 2022 | 2024 | – | – | – |
IB Works IExited 2024
SoftwareFrance· Entry 2022
France· Entry 2022Sofinnova Capital IXLife Sciences VC2018 · 8yr€333M21 active · 4 realized
Unrealized
21 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech | Switzerland | 2020 | |
| Biotech | Canada | 2019 | |
| MedTech | US | 2020 | |
| MedTech | France | 2019 | |
| Biotech | UK | 2018 | |
| Biotech | Italy | 2020 | |
| Biotech |  Austria | 2019 | |
| Biotech | US | 2019 | |
| Biotech | France | 2019 | |
| Biotech | Germany | 2018 | |
| MedTech | Ireland | 2018 | |
| Biotech | UK | 2019 | |
| MedTech | France | 2019 | |
| Biotech | US | 2020 | |
| MedTech | Israel | 2020 | |
| Biotech | Netherlands | 2018 | |
| Biotech | Canada | 2020 | |
| Biotech | US | 2019 | |
| MedTech | US | 2019 | |
| MedTech | France | 2019 | |
| MedTech | France | 2018 |
AsceneuronActive
BiotechSwitzerland· Entry 2020
Switzerland· Entry 2020Comet BiorefiningActive
BiotechCanada· Entry 2019
CorVent MedicalActive
MedTechUS· Entry 2020
US· Entry 2020CorWaveActive
MedTechFrance· Entry 2019
France· Entry 2019Crescendo BiologicsActive
BiotechUK· Entry 2018
UK· Entry 2018GenespireActive
BiotechItaly· Entry 2020
Italy· Entry 2020Hookipa PharmaActive
BiotechAustria· Entry 2019
Austria· Entry 2019HotSpot TherapeuticsActive
BiotechUS· Entry 2019
US· Entry 2019InotremActive
BiotechFrance· Entry 2019
France· Entry 2019iOmx TherapeuticsActive
BiotechGermany· Entry 2018
Germany· Entry 2018Mainstay MedicalActive
MedTechIreland· Entry 2018
Ireland· Entry 2018Mission TherapeuticsActive
BiotechUK· Entry 2019
UK· Entry 2019Moon SurgicalActive
MedTechFrance· Entry 2019
France· Entry 2019Nitrase TherapeuticsActive
BiotechUS· Entry 2020
US· Entry 2020Pi-CardiaActive
MedTechIsrael· Entry 2020
ProQR TherapeuticsActive
BiotechNetherlands· Entry 2018
Netherlands· Entry 2018PyrowaveActive
BiotechCanada· Entry 2020
BiotechUS· Entry 2019
US· Entry 2019RefleXion MedicalActive
MedTechUS· Entry 2019
US· Entry 2019SafeHealActive
MedTechFrance· Entry 2019
France· Entry 2019TissiumActive
MedTechFrance· Entry 2018
France· Entry 2018Realized
4 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech | US | 2019 | 2023 | Trade Sale | – | ||
| Biotech | Switzerland | 2020 | 2022 | – | – | ||
| Biotech | Italy | 2019 | 2025 | Trade Sale | – | ||
| MedTech | US | 2018 | 2024 | Trade Sale | – |
Sofinnova Crossover Fund IVC2018 · 8yr€549M10 active · 4 realized
Unrealized
10 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech | France | 2018 | |
| Biotech | UK | 2020 | |
| Biotech | UK | 2019 | |
| Biotech | France | – | |
| Biotech | Denmark | 2020 | |
| Biotech | France | 2019 | |
| Biotech | US | 2019 | |
| Biotech | UK | 2019 | |
| Biotech | France | 2018 | |
| Biotech | UK | 2019 |
AbivaxActive
BiotechFrance· Entry 2018
France· Entry 2018Artios PharmaActive
BiotechUK· Entry 2020
UK· Entry 2020F2GActive
BiotechUK· Entry 2019
UK· Entry 2019GenSight BiologicsActive
BiotechFrance
FranceHemab TherapeuticsActive
BiotechDenmark· Entry 2020
Denmark· Entry 2020InventivaActive
BiotechFrance· Entry 2019
France· Entry 2019MaxCyteActive
BiotechUS· Entry 2019
US· Entry 2019Redx PharmaActive
BiotechUK· Entry 2019
UK· Entry 2019SensorionActive
BiotechFrance· Entry 2018
France· Entry 2018SynthaceActive
BiotechUK· Entry 2019
UK· Entry 2019Realized
4 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech | France | 2021 | 2024 | Trade Sale | – | ||
| Biotech | Sweden | 2020 | 2024 | Trade Sale | – | ||
| MedTech | UK | 2021 | 2025 | Trade Sale | – | ||
| Biotech | UK | 2019 | 2025 | Trade Sale | – |
Sofinnova TelethonLife Sciences VC2016 · 10yr€50M5 active
Unrealized
5 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech | Italy | 2020 | |
| Biotech | Italy | 2021 | |
| Biotech | Italy | 2021 | |
| Biotech | US | 2022 | |
| Biotech | Italy | 2022 |
AAVantgarde BioActive
BiotechItaly· Entry 2020
Italy· Entry 2020Alia TherapeuticsActive
BiotechItaly· Entry 2021
Italy· Entry 2021Borea TherapeuticsActive
BiotechItaly· Entry 2021
Italy· Entry 2021BiotechUS· Entry 2022
US· Entry 2022NephrisActive
BiotechItaly· Entry 2022
Italy· Entry 2022Sofinnova Capital VIIILife Sciences VC2015 · 11yr€300M4 active · 7 realized
Unrealized
4 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech | Italy | 2015 | |
| Biotech | France | 2016 | |
| MedTech | France | 2015 | |
| Biotech | UK | 2015 |
BiovelocITAActive
BiotechItaly· Entry 2015
Italy· Entry 2015ENYO PharmaActive
BiotechFrance· Entry 2016
France· Entry 2016HighLifeActive
MedTechFrance· Entry 2015
France· Entry 2015NuCanaActive
BiotechUK· Entry 2015
UK· Entry 2015Realized
7 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech | Germany | 2016 | 2019 | Trade Sale | – | ||
| Biotech | US | 2016 | 2020 | Trade Sale | – | ||
| Biotech | UK | 2016 | 2017 | Trade Sale | – | ||
| Biotech | France | 2015 | 2018 | – | – | – | |
| Biotech | Switzerland | 2015 | 2017 | IPO | – | – | |
| MedTech | US | 2016 | 2018 | Trade Sale | – | ||
| Biotech | Switzerland | 2017 | 2023 | Trade Sale | – |
LysogeneExited 2018
BiotechFrance· Entry 2015
France· Entry 2015Sofinnova Capital VIILife Sciences VC2012 · 14yr€240M1 active · 4 realized
Realized
4 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| MedTech | France | 2012 | 2019 | Trade Sale | – | ||
| Biotech | Denmark | 2012 | 2015 | IPO | – | – | |
| Biotech | Italy | 2012 | 2013 | Trade Sale | – | ||
| Biotech | Switzerland | 2012 | 2015 | Trade Sale | – |
Sofinnova MD StartVC2010 · 16yr€30M6 active · 2 realized
Unrealized
6 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| MedTech | France | 2022 | |
| MedTech | France | 2021 | |
| MedTech | US | 2023 | |
| MedTech | France | 2022 | |
| MedTech | France | 2023 | |
| MedTech | France | 2022 |
BrightHeartActive
MedTechFrance· Entry 2022
France· Entry 2022Endoron MedicalActive
MedTechFrance· Entry 2021
France· Entry 2021MedTechUS· Entry 2023
US· Entry 2023HEPTA MedicalActive
MedTechFrance· Entry 2022
France· Entry 2022Julier MedicalActive
MedTechFrance· Entry 2023
France· Entry 2023Tulyp MedicalActive
MedTechFrance· Entry 2022
France· Entry 2022Sofinnova Capital VILife Sciences VC2008 · 18yr€260M0 active · 12 realized
Realized
12 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech | France | 2010 | 2020 | IPO | – | – | |
| Biotech | Belgium | 2008 | 2018 | Trade Sale | – | ||
| Biotech | Switzerland | 2008 | 2012 | – | – | – | |
| MedTech | France | 2007 | 2009 | Trade Sale | – | ||
| Biotech | France | 2010 | 2014 | IPO | – | – | |
| Biotech | France | 1989 | 2002 | Trade Sale | – | ||
| Biotech | France | 2000 | 2006 | IPO | – | – | |
| Biotech | Belgium | 2008 | 2010 | Trade Sale | – | ||
| Biotech | France | 2006 | 2010 | Trade Sale | – | ||
| Biotech | Germany | 2008 | 2016 | IPO | – | – | |
| Biotech | US | 2010 | 2013 | Trade Sale | – | ||
| Biotech | Switzerland | 2006 | 2010 | Trade Sale | – |
Addex TherapeuticsExited 2012
BiotechSwitzerland· Entry 2008
Switzerland· Entry 2008Track Sofinnova Partners
Saved GPs appear in your watchlist, one click from your workspace.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialised in life sciences with €4.0 billion of assets under management as of December 2024, headquartered in Paris with additional offices in London and Milan. Founded in 1972, the firm has backed more than 600 life sciences companies over a 53-year track record across multiple biotech, MedTech and HealthTech cycles. Sofinnova focuses exclusively on healthcare and sustainability themes, distinguishing the platform from generalist VC firms.
Investment thesis
Sofinnova deploys capital across complementary life sciences strategies including Biotech (drug discovery and development), MedTech (medical devices and digital health), HealthTech (digital health platforms) and selective Industrial Biotech and Sustainability themes. Investment stages span early-stage seed and Series A through growth equity and pre-IPO commitments, with equity tickets typically ranging from €5 million to €50 million per transaction. The platform's sector-exclusive focus enables deep scientific and clinical expertise across translational research, regulatory navigation and commercial scale-up.
Recent activity
Recent realised exits include PinCell (biotech, 2025), Verona Pharma (biotech, 2025), Amolyt Pharma (biotech, 2024), Betteromics (HealthTech, 2024) and Calliditas (biotech, 2024), reflecting strong distribution momentum across the biotech franchise. The platform tracks 13 funds, 107 active portfolio companies and 36 realised exits across a multi-decade track record. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
Crédit Mutuel Equity
France·€4.0B
Peugeot Invest
France·€4.2B
Edmond de Rothschild Private Equity (France)
France·€4.3B
ISALT
France·€3.0B
Seven2
France·€5.0B
Audacia
France·€2.8B
IRD Invest
France·€2.6B
Partech Partners
France·€2.5B
RGreen Invest
France·€2.5B
Atlantic Vantage Point Capital
France·€2.5B
Idia
France·€2.4B
Argos Wityu
France·€2.3BGet the full picture on Sofinnova Partners.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Save this GP to your watchlist
Saved searches that re-run your sourcing filters in one click
Geography breakdown across 17 geographies
Exit buyers and MOIC on every realized deal (Pro)
Export, compare GPs side by side (Pro)
Already a member? Sign in
Look up another firm or company
Last updated August 2026 · Sourced from public filings · Report an issue